Technological and pharmacoeconomic aspects of the development of drug for the complex therapy of acute intestinal infections

Abstract

Today combination drugs are widely used to treat acute intestinal infections (AII). Acute intestinal infections requiring comprehensive treatment with antimicrobial drugs, enterosorbents, pro- and prebiotics and immune drugs. We have developed the composition and technology of drug wchich contain nifuroxazide and plant substance plantaglucid. This combination is a modern treatment of AII, because it combination has high efficiency, safety, availability and comfortable use.The purpose of the research was development of composition and technological scheme of the original combined drug in the form of capsules “Diaplant” for the complex treatment AII and the study of its pharmacoeconomic aspects.Results and discussion. The combination of nifuroxazide with plantaglucid, which has additional microbiological and pharmacological effects, was justified. To develop of the composition and technology this combined drug, the technology of separate preparation of masses for encapsulation with using excipients of different groups was used. The technological scheme of production of “Diaplant” capsules is developed and the specification for quality control of capsules is made. ATC/DDD-methodology showed that the cost for DDD of “Diaplant” was 14,54 UAH. The total cost of the average recommended daily doses of separate drugs (nifuroxazide and Plantaglucidum) ranged from 22,13 to 38,05 UAH. The use of “Diaplant” in clinical practice allows reducing the cost of pharmacotherapy of AII from 152 to 262 %.Conclusion. The technological scheme of production of the domestic drug in capsules “Diaplant” that contains nifuroxazide and Plantaglucidum was developed for pharmacotherapy of acute intestinal infections. The developed drug “Diaplant” has high antimicrobial, anti-inflammatory, antispasmodic and detoxic activity, normalizes intestinal motility and helps to restore the intestinal microflora.